TAK-875

TAK-875

A GPR40 agonist in Phase-III trials, which activates a receptor that stimulates and regulates insulin production, enhancing insulin secretion in response to changes in serum glucose levels. It has little effect on insulin secretion when serum glucose is normal, and may reduce the risk of hypoglycaemia.